Acadia Pharmaceuticals | ACAD - Net Income


Acadia Pharmaceuticals reported $53.52M in Net Income for its fiscal quarter ending in September of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 53.52M 22.02M Sep/2026
ALKERMES USD 16.29M 15.79M Sep/2026
Alnylam Pharmaceuticals USD 2.17B 2B Sep/2026
Biogen USD 97.5M 222M Jun/2026
BioMarin Pharmaceutical USD -122.83M 167.59M Sep/2026
Bristol-Myers Squibb USD 2.16B 1.16B Sep/2026
Cara Therapeutics USD -6.8M 1.28M Mar/2026
Corcept Therapeutics USD 124.49M 82.35M Sep/2026
Cytokinetics USD -190.07M 8.69M Sep/2026
Eisai JPY 11.69B 6.55B Sep/2026
Eli Lilly USD 7.1B 301M Jun/2026
Incyte USD -784.8M 1.37B Sep/2026
J&J USD 210M 5.32B Sep/2026
Moderna USD 162M 944M Sep/2026
Neurocrine Biosciences USD 206.5M 62.1M Sep/2026
Pfizer USD 3.24B 3.49B Sep/2026
Prothena USD -18.58M 51.3M Jun/2026
PTC Therapeutics USD 83.5M 86.3M Jun/2026
Sarepta Therapeutics USD -28.46M 23.57M Sep/2026
Ultragenyx Pharmaceutical USD -118M 26M Sep/2026
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024
Vertex Pharmaceuticals USD 653.6M 446.2M Sep/2026